The fundamental mechanism by which omega-3 FA appear to mitigate risk for CHD begins
with the enrichment of membrane phospholipids with EPA and DHA. Once these long chain
n-3 FA are resident in cell membranes, they may have at least four separate effects. The relative
importance of each, their coordinated interaction and their sufficiency to explain the clinical
observations have yet to be determined.